The Compliance Case for Structured Doctor Engagement, Revisited

When we first built Connex, the compliance argument was almost secondary to the scheduling one. Hospitals and pharma teams wanted an easier way to arrange meetings. Compliance under the Uniform Code of Pharmaceutical Marketing Practices, UCPMP, was a box the product happened to check along the way. A year in, we think that ordering was backwards, and it is worth revisiting.

Why compliance should have been the headline

UCPMP requires pharma companies to be able to demonstrate that engagement with doctors is legitimate, documented, and free of anything that looks like an inducement. Phone-tag scheduling and informal WhatsApp chains, the way most doctor-pharma meetings were arranged before Connex, leave no defensible record of any of that. A compliance audit against that kind of history is painful for every pharma company we have spoken with.

Connex creates a structured, timestamped, verified record of every meeting by design, not as an add-on reporting feature. Because doctors never pay anything and never receive anything beyond the meeting itself, the verified-visit model sidesteps the inducement question almost entirely.

What a year of pilots showed us

Pharma compliance teams, not just field operations teams, have become active stakeholders in Connex renewals. In several accounts, the compliance officer is now the internal champion pushing procurement forward, not the field team that originally requested the pilot. That is a meaningful shift from a year ago, when compliance was rarely in the room during the sales conversation at all.

What this means going forward

We are treating the compliance case as a first-class part of how we describe Connex, not a footnote. That means:

• •Verification records built to the level of detail a UCPMP audit actually requires, not a generic activity log
• •Reporting formats reviewed with pharma compliance teams directly, rather than assumed from the outside
• •No feature added to Connex that would blur the line between a legitimate verified visit and anything that could resemble an inducement

Structured doctor engagement was always going to be useful. What we underestimated a year ago is how much of that usefulness, for the pharma companies actually paying for it, comes from being able to prove it happened correctly rather than from the scheduling convenience itself.